Recent advances in theranostics and oncology PET: emerging radionuclides and targets

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Annals of Nuclear Medicine Pub Date : 2025-07-27 DOI:10.1007/s12149-025-02090-z

Tadashi Watabe, Kenji Hirata, Mami Iima, Masahiro Yanagawa, Tsukasa Saida, Akihiko Sakata, Satoru Ide, Maya Honda, Ryo Kurokawa, Kentaro Nishioka, Mariko Kawamura, Rintaro Ito, Koji Takumi, Seitaro Oda, Shunsuke Sugawara, Keitaro Sofue, Daiju Ueda, Shinji Naganawa

{"title":"Recent advances in theranostics and oncology PET: emerging radionuclides and targets","authors":"Tadashi Watabe, Kenji Hirata, Mami Iima, Masahiro Yanagawa, Tsukasa Saida, Akihiko Sakata, Satoru Ide, Maya Honda, Ryo Kurokawa, Kentaro Nishioka, Mariko Kawamura, Rintaro Ito, Koji Takumi, Seitaro Oda, Shunsuke Sugawara, Keitaro Sofue, Daiju Ueda, Shinji Naganawa","doi":"10.1007/s12149-025-02090-z","DOIUrl":null,"url":null,"abstract":"<div>Theranostics, a novel integrated approach that combines cancer diagnosis and therapy by switching the radionuclide, has attracted growing attention. Various oncology PET probes other than FDG have been developed for the highly sensitive and precise detection of many types of cancer with the advancements in PET scanners, supporting the innovative development in theranostics. In therapeutic applications, radioligand therapy targeting somatostatin receptors (SSTR) and prostate-specific membrane antigen (PSMA) has already demonstrated significant clinical benefits. Terbium-161 (161Tb) has emerged as a new beta and Auger electron emitter, showing greater therapeutic efficacy compared to 177Lu. Alpha emitters, such as astatine (211At), are currently being evaluated in investigator-initiated clinical trials, with preliminary efficacy data reported for [211At]NaAt in patients with radioiodine-refractory thyroid cancer. Novel pan-tumor targeting agents, such as TROP-2, Nectin-4, LAT1, GPC-1, and EphA2, are also under development, and clinical translation of radioligand therapy is anticipated. These innovations in theranostics are expected to further broaden the scope of precision medicine in oncology.</div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 9","pages":"909 - 921"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12149-025-02090-z.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-025-02090-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Theranostics, a novel integrated approach that combines cancer diagnosis and therapy by switching the radionuclide, has attracted growing attention. Various oncology PET probes other than FDG have been developed for the highly sensitive and precise detection of many types of cancer with the advancements in PET scanners, supporting the innovative development in theranostics. In therapeutic applications, radioligand therapy targeting somatostatin receptors (SSTR) and prostate-specific membrane antigen (PSMA) has already demonstrated significant clinical benefits. Terbium-161 (¹⁶¹Tb) has emerged as a new beta and Auger electron emitter, showing greater therapeutic efficacy compared to ¹⁷⁷Lu. Alpha emitters, such as astatine (²¹¹At), are currently being evaluated in investigator-initiated clinical trials, with preliminary efficacy data reported for [²¹¹At]NaAt in patients with radioiodine-refractory thyroid cancer. Novel pan-tumor targeting agents, such as TROP-2, Nectin-4, LAT1, GPC-1, and EphA2, are also under development, and clinical translation of radioligand therapy is anticipated. These innovations in theranostics are expected to further broaden the scope of precision medicine in oncology.

查看原文本刊更多论文

治疗学和肿瘤学PET的最新进展：新出现的放射性核素和靶标。

治疗学是一种通过转换放射性核素将癌症诊断和治疗结合起来的新型综合方法，引起了越来越多的关注。随着PET扫描仪的进步，除了FDG之外，各种肿瘤学PET探针已经被开发出来，用于对许多类型的癌症进行高度敏感和精确的检测，支持治疗学的创新发展。在治疗应用方面，针对生长抑素受体（SSTR）和前列腺特异性膜抗原（PSMA）的放射配体治疗已经显示出显著的临床益处。Terbium-161 （161Tb）作为一种新的β和俄歇电子发射器出现，与177Lu相比，显示出更大的治疗效果。α发射器，如astatine (211At)，目前正在研究者发起的临床试验中进行评估，[2111at]NaAt对放射性碘难治性甲状腺癌患者的初步疗效数据报道。新的泛肿瘤靶向药物，如TROP-2、Nectin-4、LAT1、GPC-1和EphA2也在开发中，预计放射配体治疗的临床转化。这些治疗学上的创新有望进一步拓宽肿瘤精准医学的范围。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Nuclear Medicine 医学-核医学

CiteScore

4.90

自引率

7.70%

发文量

111

审稿时长

4-8 weeks

期刊介绍： Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.